Biomarkers News: Breaking Biomarkers News, Comments and Articles.

Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group

The ECOG-ACRIN Cancer Research Group announced today that it has appointed Joseph A. Sparano, MD, as its Vice Chair. In his new role, Dr. Sparano will assist the Group leadership in defining research priorities and implementing its broad research portfolio, which includes programs in Cancer Control and Outcomes, Therapeutic Studies, and Biomarker Sciences. Atlanta, GA (PRWEB) May 17, 2013 Dr. Spa...

Ysios and Axis provide [STAT-Diagnostica & Innovation] with €2mm Series A financing

[STAT-Diagnostica & Innovation SL] (near-patient testing systems that integrate molecular diagnostics and immunoassays to provide rapid results in acute care settings) raised €2mm ($3mm) in its Series A financing. Ysios Capital Partners and Institu...

Genomind Demonstrates Broader Commitment to the Mental Health Community

CHALFONT, PA--(Marketwired - May 17, 2013) -  Genomind, a personalized medicine company, is pleased to announce that we will attend and present at the American Psychiatric Association (APA) Annual Meeting, held May 18 - 22, 2013, in San Francisco at the Moscone Center. The APA Annual Meeting is a hands-on learning convention designed to help practicing professionals in all levels of psychiatric r...

Identification of biomarkers for Mycobacterium tuberculosis infection and disease in BCG-vaccinated young children in Southern India

Eisai Highlights New Research On Melanoma, Breast and Endometrial Cancer at ASCO Annual Meeting

WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Eisai Inc. announced today that nine abstracts highlighting new study results in melanoma, breast and endometrial cancer will be presented during the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 31 - June 4, 2013. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )...

Chronix Biomedical Announces Multiple Poster Presentations at ASCO 2013

Data Highlight Next-Generation Sequencing of Cell-Free DNA to Detect Minimal Residual Disease in a Variety of Cancers Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, announces that four research abstracts highlighting the Company’s cell-free DNA technology for real-time cancer detection will be presented at the American So...

American Heart Association Honors Saint Luke's Cardiologist

KANSAS CITY, Mo., May 16, 2013 /PRNewswire-USNewswire/ -- Cardiologist John Spertus, M.D., M.P.H., Medical Director of Outcomes Research at Saint Luke's Mid America Heart Institute and the Lauer/Missouri Endowed Chair and Professor of Medicine at the University of Missouri – Kansas City has been named the recipient of the American Heart Association's Council on Quality of Care and Outcomes R...

Advances and perspectives on biomarkers

Dr Normanno discusses individualized therapy and developments in screening patients for gene mutations. Previously only KRas and EGFR were screened for; however, there is now the ability to look for an exponentially larger amount for each patient. ...

Biomarker analyses in emerging data from PI3K/AKT/mTOR programme clinical trials

ecancer reporter Peter Goodwin talks to Dr Ana Vivancos at the 2013 IMPAKT meeting in Brussels about her research in to enrolement strategies in Phase I clinical trials. Dr Vivancos offers advice on the assessment of different mutations and what...

Novel RNA detection reagent enables gene expression analysis in living cells

In this new application note, Millipore describes how a Novel RNA detection reagent enables gene expression analysis in living cells. This technology allows for carrier- free cellular endocytosis of the reagent, followed by detection and relative quantitative analysis of RNA levels. Because the reagent leaves the cell after the detection event, the same sample can be used for any downstream analys...

DiagnoCure announces presentation on Previstage GCC at the 2013 ASCO annual meeting

New findings validate clinical utility in Colorectal Cancer Staging MONTREAL, May 16, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"), today announced that results from a large validation study of the PrevistageTM GCC Colorectal Cancer Staging Test have been selected for presentation at the 2013 American Society of Clinical Oncology® (ASCO®) Annual...

Biomarker Discovered for Pregnancy-Related Heart Disease

A molecule has been identified that can serve as a biomarker for peripartum cardiomyopathy that occurs in pregnant women during...

Detect Alzheimer's Disease Years Before Memory Loss And Cognitive Decline Become Apparent

Scientists at Washington University School of Medicine in St. Louis have helped identify many of the biomarkers for Alzheimer's disease that could potentially predict which patients will develop the disorder later in life. Now, studying spinal fluid...

Eutropics Pharmaceuticals to Present Data on Personalized Diagnostic for AML Patient Management at ASCO 2013

Study using Novel Biomarker Technology Indicates Potential Medical Utility in Discriminating Clinical Outcomes Eutropics Pharmaceuticals Inc. announced today that Eutropics and The University of Texas MD Anderson Cancer Center will present results from a clinical study employing Eutropics’ proprietary PraediCare Dx (BH3 profiling) assay to discrimina...

Giving teriparatide with denosumab improves bone density

Combining teriparatide (Forsteo) with denosumab (Prolia) increases bone mineral density (BMD) in postmenopausal women with osteoporosis more than either drug alone, according to research published online in The Lancet today (15 May 2013). Moreover,...

New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating m...

Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting

FLEMINGTON, N.J., May 15, 2013 /PRNewswire/ -- Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced new, positive data from three studies supporting its investigational compound onapristone to be presented at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting, which is being hel...

Vermillion Reports First Quarter 2013 Results

AUSTIN, Texas, May 15, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, reported on its financial results for the first quarter ended March 31, 2013. Q1 2013 Financial ResultsTotal revenue in the first quarter of 2013 was $328,000, compared to $312,000 in the same year-ago quarter. First quarter 2013 revenue w...

Emerging Biomarker Companies Redux: Positioned For Growth

By Rod Raynovich: Biomarker Products for Cardiovascular Disease and Cancer This is the third article on Emerging Biomarker Companies. See 11/15/12 UpdateThe synergies between diagnostics and drugs are growing as more treatment options require better data for cost-effective, targeted therapeutics.The development of unique biomarkers has been considered the "Holy Grail" of innovation in diagnostic...

US FDA expands use of Roche’s lung cancer drug; approves genetic test

The Food and Drug Administration has expanded the use of Roche subsidiary Genentech's advanced lung cancer drug, Tarceva (erlotinib). Tarceva is now the first personalised medicine approved for patients with EGFR mutation-positive advanced non-small...

Director of Proteomics at the Broad Institute of MIT and Harvard, Steven Carr, to Deliver Pittcon 2014 Wallace H. Coulter Plenary Lecture

The Pittcon Program Committee is pleased to announce that Steven Carr, director of proteomics at the Broad Institute of MIT and Harvard, will deliver the Wallace H. Coulter Plenary Lecture at PIttcon 2014. Pittsburgh, PA (PRWEB) May 15, 2013 Dr. Carr is internationally recognized as a leader in the development of novel proteomics methods and in their application in biology and medicine. Dr. Carr...

New Evidence Shows Hysterectomy Does Not Increase Risk Of Heart Disease

Brett Smith for redOrbit.com - Your Universe Online While previous research has shown a connection between the medical removal of a woman’s uterus and heart problems, a new study in the Journal of the American College of Cardiology has found no evidence of an increased risk. Commonly referred to as a hysterectomy, the removal of the uterus is the second most common surgery among American women...

Adaptive, BMS ink biomarker discovery collaboration agreement

Adaptive Biotechnologies, a Seattle-based developer of next generation sequencing assays, has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology.

Multitarget FISH testing in lung cancer

Dr Lucas Bubendorf explains the process of multitarget fluorescence in situ hybridization (FISH), other lung cancer biomarkers, immunochemistry and testing modalities. Filming supported by Amgen

CVCA Board Certified Veterinary Cardiologists Conducting New Feline Atenolol Study for Survival Benefits of Treatment, Recently Interviewed for Cardiac Specialty on Fox 5

Chesapeake Veterinary Cardiology Associates (CVCA), the largest Board Certified Veterinary Cardiologist group with nine locations in Maryland and Virginia is conducting a new Feline Patient Atenolol study by Dr. Neal Peckens, DVM, Diplomate, ACVIM (Cardiology) and were recently featured on a “Be Kind to Animals Week” segment on Fox 5 in Washington, DC...